EICHORPublic-registry trials using Siltuximab that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) | Merck Sharp & Dohme LLC | Chronic Lymphocytic Leukaemia | PHASE2 | 0 |
| First FDA approval | SYLVANT — April 2014 (application BLA125496, currently held by RECORDATI RARE DISEASES, INC.) |
| Also known as | SYLVANT |
| Approved applications | 1 |
| Forms & routes | Injectable · Injection |
| Registry-wide use | 45 registered studies all-time · 8 currently recruiting |
Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Chronic Lymphocytic Leukaemia drugs
← Eichor home · All tracked trials · Chronic Lymphocytic Leukaemia studies · Weekly briefs
